Parallax Volatility Advisers’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-22,303
Closed -$311K 2617
2023
Q2
$554K Buy
+22,303
New +$576K ﹤0.01% 1614
2022
Q3
Sell
-4,245
Closed -$18K 3355
2022
Q2
$18K Sell
4,245
-46,594
-92% -$291K ﹤0.01% 2600
2022
Q1
$483K Buy
50,839
+27,226
+115% +$315K ﹤0.01% 1917
2021
Q4
$449K Sell
23,613
-21,075
-47% -$547K ﹤0.01% 1483
2021
Q3
$1.49M Buy
+44,688
New +$1.38M ﹤0.01% 1214
2021
Q2
Sell
-3,831
Closed -$150K 1713
2021
Q1
$185K Buy
+3,831
New +$184K ﹤0.01% 1077
2020
Q1
Sell
-1,107
Closed -$12K 2715
2019
Q4
$12K Buy
+1,107
New +$8.42K ﹤0.01% 2318
2019
Q2
Sell
-14,800
Closed -$112K 3707
2019
Q1
$119K Buy
+14,800
New +$80K ﹤0.01% 2078
2018
Q4
Sell
-34,986
Closed -$196K 3932
2018
Q3
$196K Buy
+34,986
New +$400K ﹤0.01% 1629
2018
Q1
Sell
-7,392
Closed -$61K 4143
2017
Q4
$61K Buy
+7,392
New +$64.6K ﹤0.01% 3110
2016
Q2
Sell
-25,000
Closed -$213K 3524
2016
Q1
$213K Buy
25,000
+5,803
+30% +$50.8K ﹤0.01% 1740
2015
Q4
$229K Buy
+19,197
New +$242K ﹤0.01% 1843

Other funds holding TGTX

Parallax Volatility Advisers's TGTX Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 22,303 shares — an estimated $311K sold.

Parallax Volatility Advisers first reported a position in TGTX in Q4 2015 and held it in 12 quarters. The position peaked at $1.49M in Q3 2021. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Parallax Volatility Advisers reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 22,303 TG Therapeutics shares in Q3 2023, an estimated $311K.
  • Parallax Volatility Advisers first reported a position in TG Therapeutics in Q4 2015 and held it in 12 quarters.
  • Parallax Volatility Advisers's TG Therapeutics position peaked at $1.49M in Q3 2021.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.